| Literature DB >> 28553091 |
Marita Kloseck1,2, Deborah A Fitzsimmons1,3,4, Mark Speechley5, Marie Y Savundranayagam1, Richard G Crilly1,2.
Abstract
BACKGROUND: This randomized controlled trial (RCT) evaluated a 6-month peer-led community education and mentorship program to improve the diagnosis and management of osteoporosis.Entities:
Keywords: bone mineral density; capacity building; community knowledge translation; mentor; prevention; seniors
Mesh:
Year: 2017 PMID: 28553091 PMCID: PMC5440001 DOI: 10.2147/CIA.S130573
Source DB: PubMed Journal: Clin Interv Aging ISSN: 1176-9092 Impact factor: 4.458
Description of the education modules, including objectives, curriculum, and instructors
| Module | Instructor | Objectives | Curriculum |
|---|---|---|---|
| 1. What is osteoporosis? | Geriatrician | Answer the question “what is osteoporosis?”; recognize causes of bone loss; discuss the relationship between osteoporosis and fractures and the consequences of osteoporotic fractures in terms of one’s health and quality of life; assess their own, and others’, risk of osteoporosis; outline action plans for individuals at varying levels of osteoporosis risk (ie, suggestions for successful patient–physician interactions); understand the medical assessments used to diagnose osteoporosis, who should be assessed, and what to expect during a BMD or heel ultrasound | 1) What is osteoporosis?; 2) bone formation and bone loss; 3) osteoporosis and fractures; assessing your osteoporosis risk factors; 4) action plans for individuals at risk of osteoporosis; 5) diagnosing osteoporosis: what to expect |
| 2. Physical activity and osteoporosis | Physiotherapist | Explain how physical activity affects bone mass (at the level of a lay person); provide practical examples of weight-bearing and resistance exercises; highlight the exercise precautions that should be taken by individuals with osteoporosis | 1) Effect of physical activities on bone health; 2) exercise precautions for people with osteoporosis; 3) practical examples of weight-bearing and resistance exercises; 4) maintaining good posture to protect your back |
| 3. Drug therapies for the treatment and prevention of osteoporosis | Endocrinologist | Understand how drug therapies work (at the level of a lay person); provide a brief overview of the primary classes and brands of drug therapies used to prevent and treat osteoporosis (at the level of a lay person); emphasize the significant increase in the incidence of male osteoporosis | 1) How drug therapies work; 2) common osteoporosis medications; 3) what about male osteoporosis?; 4) how long should I continue taking my medication? |
| 4. Nutrition and osteoporosis | Registered dietician | Explain the role of calcium and vitamin D in preventing and treating osteoporosis; inform their peers of their required amount of daily calcium; recommend methods of maximizing dietary calcium intake; understand the role of calcium and vitamin D supplements in preventing and treating osteoporosis, when calcium and vitamin D intake should be supplemented, how to choose and how to take a supplement | 1) Calcium is essential for healthy bones; 2) using diet to maximize your daily calcium intake; 3) vitamin D’s role in preventing osteoporosis; 4) when you cannot get enough calcium and vitamin D from your diet |
| 5. Living with osteoporosis and protecting your back | Occupational therapist | Discuss the physical consequences and challenges of living with osteoporosis; provide practical suggestions to effectively practice safe movements, complete household chores safely, and eliminate fall hazards in one’s home; provide contact information for Osteoporosis Canada. | 1) Physical consequences of living with osteoporosis; 2) protecting your bones; 3) how to move safely; 4) how to safely complete your household activities; 5) eliminate fall hazards from your home. |
Abbreviation: BMD, bone mineral density.
Figure 1Risk assessment and action plan tool.
Figure 2Consolidated Standards of Reporting Trials 2010 flow diagram.
Baseline characteristics of participants
| Variables | Intervention group (n=53) | Control group (n=52) |
|---|---|---|
| Sociodemographic variables | ||
| Female n (%) | 47 (88.7) | 46 (88.5) |
| Mean age in years (SD) | 81 (6.9) | 80 (7.0) |
| Marital status n (% married) | 11 (20.8) | 14 (26.9) |
| Level of education n (% postsecondary) | 19 (35.8) | 21 (40.4) |
| Risk assessment n (% yes) | ||
| Previous fractures | 16 (30.2) | 23 (44.2) |
| Spine | 2 (3.8) | 3 (5.8) |
| Wrist | 8 (13.2) | 15 (28.8) |
| Upper arm | 3 (5.7) | 5 (9.6) |
| Hip | 3 (5.7) | 2 (3.8) |
| Pelvis | 3 (5.7) | 3 (5.8) |
| Rib(s) | 6 (11.3) | 5 (9.6) |
| Maternal hip fracture | 6 (11.3) | 4 (7.7) |
| Has become shorter with age | 32 (60.4) | 39 (75.0) |
| Has fallen in the past year | 23 (43.4) | 18 (34.6) |
| Has ever had a BMD completed | 28 (52.8) | 36 (69.2) |
| Takes calcium supplements | 35 (66.0) | 36 (69.2) |
| Takes vitamin D supplements | 36 (67.9) | 35 (67.3) |
| Takes a multivitamin pill | 25 (47.2) | 28 (53.8) |
| Prescription medication n (% yes) | ||
| Osteoporosis medication use | 13 (26.4) | 14 (28.8) |
| Fosamax (alendronate) | 3 (5.7) | 8 (15.4) |
| Actonel (risedronate) | 6 (11.3) | 5 (9.6) |
| Didrocal (etidronate/calcium) | 3 (5.7) | 1 (1.9) |
| Evista (raloxifene) | 1 (1.9) | 1 (1.9) |
| Miacalcin nasal spray (calcitonin) | 0 (0.0) | 0 (0.0) |
| Estrogen or HRT | 2 (3.8) | 1 (1.9) |
Note:
Some participants were on >1 medication.
Abbreviations: SD, standard deviation; BMD, bone mineral density; HRT, hormone replacement therapy.
Change in osteoporosis behavior and knowledge
| Variables | Intervention group (n=41) | Control group (n=43) | Odds ratio (95% CI) | Mean difference | |
|---|---|---|---|---|---|
| Frequency of successful outcome | 30 (73) | 13 (30) | 0.16 (0.06–0.42) | <0.001 | |
| Knowledge test (outcome 2) mean points | |||||
| Baseline | 30.9 (5.3) | 31.9 (4.0) | |||
| 6-month follow-up | 31.8 (4.7) | 31.1 (4.7) | |||
| Knowledge change score | 0.3 (4.7) | −1.0 (4.8) | 1.3 (−0.76 to 3.36) | 0.21 | |
Notes:
Defined as obtaining a BMD assessment; returning to their family physician to review their risk profile and to obtain BMD results; receiving treatment recommendations.
Test scores were calculated by summing correct responses minus the incorrect responses and adding 25; maximum total score =44.
Two-sample independent t-test of difference in knowledge change scores; t82df =1.25.
The baseline score is for all participants whereas the change score represents the participants who completed both tests.
Abbreviations: SD, standard deviation; BMD, bone mineral density; CI, confidence interval.
Adequacy of vitamin D intake in the intervention group
| Follow-up
| n | ||
|---|---|---|---|
| Adequate | Inadequate/none | ||
| Baseline | |||
| Adequate | 7 | 3 | 10 |
| Inadequate/none | 12 | 19 | 31 |
| n | 19 | 22 | 41 |
Note: There was an increase in the number of participants taking adequate vitamin D from 10/41 (24.4%) to 19/41 (46.3%) (McNemar’s chi-square P=0.02).